Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)
Condition(s):Medical OncologyLast Updated:July 12, 2017Terminated
Hide Studies Not Open or Pending
Condition(s):Medical OncologyLast Updated:July 12, 2017Terminated
Condition(s):Gastric Cancer; Gastroesophageal Junction AdenocarcinomaLast Updated:January 16, 2024Recruiting
Condition(s):Cholangiocarcinoma,AdultLast Updated:January 31, 2024Not yet recruiting
Condition(s):Intrahepatic CholangiocarcinomaLast Updated:June 22, 2021Withdrawn
Condition(s):Solid TumorLast Updated:June 5, 2023Completed
Condition(s):Gastric CancerLast Updated:January 7, 2020Completed
Condition(s):Solid Tumor; FGF Receptor Gene Mutation; FGF Amplification; FGF Receptor Gene Family Rearrangement; FGF Receptor Gene TranslocationLast Updated:September 1, 2023Recruiting
Condition(s):Cholangiocarcinoma; FGFR2 Fusion; FGFR2 Gene Mutation; FGFR1 Alteration; FGFR3 AlterationLast Updated:January 3, 2024Active, not recruiting
Condition(s):FGFR2 Amplification; FGFR2 Gene Mutation; FGFR2 Gene Fusion/Rearrangement; FGFR2 Gene Translocation; FGFR2 Gene Activation; Intrahepatic Cholangiocarcinoma; Cholangiocarcinoma; Other Solid Tumors, AdultLast Updated:March 5, 2024Active, not recruiting
Condition(s):Freeman-Burian Syndrome; Freeman-Sheldon Syndrome; Whistling Face Syndrome; Sheldon-Hall Syndrome; Freeman-Sheldon Syndrome Variant; Arthrogryposis Distal Type 1; Arthrogryposis Distal Type 3; Gordon SyndromeLast Updated:July 19, 2022Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.